Erin Quirk is President, Head of R&D of Terns Pharmaceuticals, Inc.. Currently has a direct ownership of 75,000 shares of TERN, which is worth approximately $426,000. The most recent transaction as insider was on Jan 23, 2024, when has been sold 75,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 75K
0% 3M change
n/a 12M change
Total Value Held $426,000

Erin Quirk Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 23 2024
BUY
Grant, award, or other acquisition
-
75,000 Added 50.0%
75,000 Common Stock
EQ

Erin Quirk

President, Head of R&D
Foster City, CA

Track Institutional and Insider Activities on TERN

Follow Terns Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TERN shares.

Notify only if

Insider Trading

Get notified when an Terns Pharmaceuticals, Inc. insider buys or sells TERN shares.

Notify only if

News

Receive news related to Terns Pharmaceuticals, Inc.

Track Activities on TERN